After a trading halt, I notice today that PNV's share price is up over 10% on news that the US regulators were changing the way they reimburse doctors. Currently doctors get reimbursed a percentage of the cost of the procedure, so there is a disincentive for doctors to offer lower cost options like what ARX and PNV offer. The US Medicare system is now proposing a flat $806 per square inch reimbursement for outpatient skin substitute products. The reason for the PNV share price increase is they will likely have increased sales, as doctors will now more likely recommend lower cost options.
Here is the announcement - https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02988143-3A675419&v=c2533a54e2514fb77a8f93f84db686e1125273e9
My issue is why was there no trading halt and subsequent announcement by the management of Aroa. Surely the change in policy would be equally applicable to Aroa.
(20min delay)